All News
Filter News
Found 806,159 articles
-
R1 Introduces R1 Entri™ Platform to Comprehensively Transform Patient Access and Experience Across Care Settings
8/9/2021
R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today introduced R1 Entri™, an intelligent patient engagement solution, at booth #4721 at the HIMSS21 Global Health Conference & Exhibition in Las Vegas.
-
Navrogen Closes $3.0M Seed Financing To Advance Its Preclinical Pipeline Targeting Humoral Immunosuppressed Cancers And Immune-Related Disorders
8/9/2021
Navrogen, Inc., a privately held preclinical biotechnology company, announced today that it has raised $3.0M from an equity financing to support its Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities.
-
Epizyme Announces CEO Succession
8/9/2021
Epizyme, Inc., a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies announced its Chief Executive Officer succession plan, with industry veteran Grant Bogle succeeding Robert Bazemore, as President and CEO.
-
Dante Labs Announces Appointment of Healthcare Veteran and GRAIL SVP Mark Morgan to Board Of Directors to Support Genomic and Precision Medicine Scaling in the United States
8/9/2021
Dante Labs announced today the appointment of Mark Morgan as a board member.
-
ClearPoint Neuro, Inc. Announces Strategic and Commercial Partnership with European Surgical Equipment Leader adeor medical AG
8/9/2021
ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it has entered into a strategic and commercial partnership with German-based surgical equipment leader adeor medical AG for powered neurosurgical drill solutions.
-
Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada
8/9/2021
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that recruitment is open to patients in Canada for the Phase 3 pivotal clinical program of OPT-302 for the treatment of wet age-related macular degeneration.
-
Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M
8/9/2021
Liminal BioSciences Inc., announced today that, its subsidiary Prometic Biotherapeutics Inc. has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for USD105M.
-
Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights
8/9/2021
Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, reported financial results for the second quarter ended June 30, 2021, and provided an overview of recent operational highlights and a pipeline update.
-
Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis
8/9/2021
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) accepted for filing the company’s New Drug Application (NDA) for DARE-BV1 for the treatment of bacterial vaginosis.
-
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19
8/9/2021
Cytocom Inc. today provided an update regarding its portfolio of clinical programs.
-
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 09, 2021
8/9/2021
KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 20,000 shares of KalVista common stock on August 3, 2021 as inducements material to each employee entering into employment with KalVista.
-
ADMA Biologics Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM® and NABI-HB®
8/9/2021
ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commercial availability of additional vial sizes of BIVIGAM and NABI-HB, which are currently in stock and commercially available to U.S healthcare providers and patients.
-
Healthcare Data Startup H1 Acquires Carevoyance, Accelerating Entry into the Fast-Growing Medical Device Market
8/9/2021
H1, which provides the largest global healthcare platform that connects healthcare professionals, announced today that it has acquired Portland, Oregon based Carevoyance, which offers the best targeting, sales enablement, and physician segmentation platform to medical device sellers.
-
Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update
8/9/2021
Epizyme today reported its second quarter 2021 financial results and provided a business update.
-
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline
8/9/2021
Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), a subsidiary of Otsuka Pharmaceutical Co., Ltd., announces that it has been awarded a grant for up to $17.8 million from the Bill & Melinda Gates Foundation.
-
Rheos Medicines Appoints Nirupama Subramanian as Chief Operating Officer
8/9/2021
Brings leadership experience from Agios Pharmaceuticals and Novartis Vaccines with strategy and operations expertise across many stages of product development and company growth
-
Trevena to Release Second Quarter 2021 Financial Results on August 12th, 2021
8/9/2021
Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that it will release its financial results for the second quarter ended June 30, 2021, prior to the market open on Thursday, August 12th, 2021.
-
Inflammasome Therapeutics to Develop Dual Sustained-Release HIV Prevention and Birth Control Implant
8/9/2021
Inflammasome Therapeutics, a private, science-based company developing therapies for prevalent, degenerative diseases and sustained-release drug delivery systems, announced it has been awarded a second grant from the Bill & Melinda Gates Foundation.
-
Avinger Announces 510(k) Filing for New Lightbox 3 Imaging Console
8/9/2021
Avinger, Inc. today announced the submission of a 510(k) application to the U.S. Food & Drug Administration (FDA) for its new Lightbox 3 imaging console.
-
Cybin to Present at Canaccord Genuity’s 41st Annual Growth Conference on August 10th
8/9/2021
Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced that Doug Drysdale, Chief Executive Officer, will be presenting virtually at Canaccord Genuity’s 41st Annual Growth Conference on August 10, 2021.